Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,263 across all filing types
Latest filing 2023-02-10 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Financial Result Updates
Regulatory Filings
2023-02-10 English
In continuation of our letter dated January 30, 2023, we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e., Friday, February 10, 2023 inter alia ....
Regulatory Filings
2023-02-10 English
Outcome of Board Meeting
Regulatory Filings
2023-02-10 English
In continuation of our letter dated January 30, 2023, we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e., Friday, February 10, 2023 inter alia ....
Regulatory Filings
2023-02-10 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about an upcoming Board of Directors meeting scheduled for February 10, 2023, to consider and approve unaudited financial results for the quarter and nine months ended December 31, 2022. It also mentions the closure of the trading window for insider trading compliance. The document does not contain any financial data or detailed results itself, nor does it include a full report. It is essentially an announcement of a board meeting and related compliance information. Given the short length (1517 characters) and the nature of the content, this fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than a full Interim Report (IR) or Earnings Release (ER).
2023-01-30 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the loss of share certificates. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, specifically Regulation 39(3), which pertains to share certificate loss and related disclosures. The content is an announcement about a shareholder's lost share certificates, not a financial report, meeting material, or management discussion. It is a regulatory disclosure related to shareholding records but does not fit into categories like Major Shareholding Notification (MRQ) since it is about lost certificates, not ownership changes. It is also not a report publication or certification. Therefore, the best fitting category is Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other specific categories.
2023-01-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.